Results 231 to 240 of about 176,773 (340)

Early appearance of lateral pharyngeal outpouchings: Significant association with dysphagia. An indication of pharyngeal dysfunction?

, 1986
David J. Curtis, David F. Cruess
openalex   +1 more source

Pharmacological Treatment of Dysphagia in Stroke [PDF]

, 1997
David Smithard, Nicolas Pérez‐Fernández, Lalit Kalra   +2 more
openalex   +1 more source

Large Anterior Cervical Spine Schwannoma Causing Dysphagia: Case Report. [PDF]

Int Med Case Rep J
Joniec A, Mikolajczyk J, Godlewski B.
europepmc   +1 more source

Food—Consistency/Texture—Specific Pharyngeal Dystonia: A Novel Form of Focal Task‐Specific Dystonia

Movement Disorders Clinical Practice, EarlyView.
Domenico A. Restivo, Daniele Bruschetta, Angelo Alito, Enrico Alfonsi, Rosario Marchese‐Ragona, Angelo Quartarone   +5 more
wiley   +1 more source

A Phase 1, Double‐Blind, Placebo‐Controlled Trial of Sevasemten (EDG‐5506), a Selective Modulator of Fast Skeletal Muscle Contraction, in Healthy Volunteers and Adults With Becker Muscular Dystrophy

Muscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims Sevasemten (EDG‐5506) is an orally administered, investigational small molecule that selectively modulates fast muscle fiber contraction by inhibiting fast myosin ATPase. This study assessed the safety, tolerability, and pharmacokinetics (PK)/pharmacodynamics (PD) of sevasemten in healthy adult volunteers (HVs) and adults ...
Joanne Donovan, Jeffrey A. Silverman, Ben Barthel, Michael DuVall, Molly Madden, James MacDougall, Nicole Rempel Kilburn, Abby Bronson, Marc Evanchik, Gilad Gordon, Kevin Koch, Alan J Russell   +11 more
wiley   +1 more source

Letter to the Editor: Association Between Dysphagia and Symptoms of Depression and Anxiety After Ischemic Stroke. [PDF]

Eur J Neurol
Wu L, Jiao Z, Ma Y, Chang G.
europepmc   +1 more source

Efficacy and Safety of Once Daily Dosing vs. Approved On/Off Dosing of Edaravone Oral Suspension Up to 48 Weeks in Patients With Amyotrophic Lateral Sclerosis (Study MT‐1186‐A02)

Muscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims An On/Off dosing regimen of intravenous (IV) edaravone and edaravone oral suspension is approved in the US for the treatment of amyotrophic lateral sclerosis (ALS). Placebo‐controlled clinical trials showed IV edaravone slows the rate of physical functional decline.
Jeffrey Rothstein, Angela Genge, Shari De Silva, Lorne Zinman, Marvin Chum, Adriano Chio, Gen Sobue, Masashi Aoki, Hiide Yoshino, Manabu Doyu, Daniel Selness, Vesna Todorovic, Nissim Sasson, Manabu Hirai, Fumihiro Takahashi, Alejandro Salah, Art Wamil, Stephen Apple   +17 more
wiley   +1 more source

SURGICAL TREATMENT OF THE THORACOABDOMINAL AORTIC ANEURYSM WITH DYSPHAGIA

, 1991
Hideyuki Harada, Y Ichimiya, Mutsumi Ueda   +2 more
openalex   +2 more sources

Dysphagia After Pediatric Laryngotracheal Reconstruction-A Scoping Review. [PDF]

Laryngoscope Investig Otolaryngol
Singh N, Chorney SR, Johnson RF, Teplitzky TB.   +3 more
europepmc   +1 more source

Safety Extension Study of Edaravone Oral Suspension in Patients With Amyotrophic Lateral Sclerosis for up to an Additional 96 Weeks of Treatment

Muscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims Edaravone intravenous (IV) and oral suspension have been shown to have similar pharmacokinetics, safety, and slowing of functional decline in patients with amyotrophic lateral sclerosis (ALS). Study MT‐1186‐A01 indicated that edaravone oral suspension was well‐tolerated over 48 weeks, with no new safety concerns identified ...
Angela Genge, Gary L. Pattee, Gen Sobue, Masashi Aoki, Hiide Yoshino, Philippe Couratier, Christian Lunetta, Susanne Petri, Daniel Selness, Vesna Todorovic, Nissim Sasson, Manabu Hirai, Fumihiro Takahashi, Alejandro Salah, Stephen Apple, Art Wamil, Alexander Kalin, Carlayne E. Jackson   +17 more
wiley   +1 more source